Search

Your search keyword '"Maloisel, F."' showing total 493 results
Start Over Author "Maloisel, F."
493 results on '"Maloisel, F."'

57. [Drug-induced agranulocytosis in rheumatology. A retrospective study of 12 cases]

Author

Serraj K, Federici L, Maloisel F, Jean Sibilia, and Andrès E

Subjects
Adult, Male, Adolescent, Antirheumatic Agents, Patient Selection, Rheumatic Diseases, Humans, Female, Middle Aged, Aged, Agranulocytosis, Retrospective Studies
Abstract

the aim of this study is to determine the clinical characteristics of drug-induced agranulocytosis in rheumatology.it is a retrospective monocentric study, including all cases of rheumatologic drug-induced agranulocytosis followed between January 1985 and December 2005.eight female and 4 men, mean age 62.5 years (range: 17-79), were included in the present study. The causative drugs were: anti-inflammatory agents (n=5, 41.6%), methotrexate (n=3, 25%), sulfasalazine (n=2, 16.6%), noramidopyrine (n=1) and dapsone (n=1). Main clinical features included infectious disorders in 9 cases (75%) with 4 cases of septicemia (33.3%) and 2 cases of septic shock (16.6%). The mean neutrophils count was 0.132 x 10(9)/L (range, 0-0.4). Outcome was favorable in 11 patients (91.6%). One patient died of septic complications.in rheumatology, drug-induced agranulocytosis is a rare but life-threatening disorder.

Published
2007

58. Idiosyncratic drug-induced neutropenia and agranulocytosis.

Author

Andrès, E., Mourot-Cottet, R., Maloisel, F., Séverac, F., Keller, O., Vogel, T., Tebacher, M., Weber, J.-C., Kaltenbach, G., Gottenberg, J.-E., Goichot, B., Sibilia, J., Korganow, A.-S., and Herbrecht, R.

Subjects
IDIOSYNCRATIC drug reactions, NEUTROPENIA, AGRANULOCYTOSIS, PNEUMONIA, TONSILLITIS
Abstract

Background/Introduction: Few data is currently available on neutropenia and agranulocytosis related to drug intake. Aim: We report here data on 203 patients with established idiosyncratic drug-induced agranulocytosis, followed up in a referral centre within a university hospital. Design: Data from 203 patients with idiosyncratic drug-induced agranulocytosis were retrospectively reviewed. Methods: All cases were extracted from a cohort study on agranulocytosis in the Strasbourg University Hospital (Strasbourg, France). Results: The mean age was 61.6 years old (range: 18-95), the gender ratio (F/M) was 1.3. Several comorbidities were present in 63.5%. The most frequent causative drugs were: antibiotics (49.3%), especially b-lactams and cotrimoxazole; antithyroid drugs (16.7%); neuroleptic and anti-epileptic agents (11.8%); antiviral agents (7.9%); and platelet aggregation inhibitors as ticlopidine and acid acetylsalicylic (6.9%). The main primary clinical manifestations during hospitalization included: isolated fever (26.3%); septicaemia (13.9%); documented pneumonia (13.4%); sore throat and acute tonsillitis (9.3%); and septic shock (6.7%). The mean neutrophil count at nadir was 0.148 × 109/L (range: 0-0.48). All febrile patients were treated with broad-spectrum antibiotics and 107 (52.7%) with hematopoietic growth factors. The mean duration of haematological recovery (neutrophil count ⩾1.5 × 109/L) was 7.8 (range: 2-20). This mean duration was reduced to 2.1 days (range: 2-16) (p=0.057) with hematopoietic growth factors. Outcome was favourable in 91.6% of patients; seventeen died. Thirty-seven patients (18.2%) required intensive care. Discussion/Conclusion: The present study demonstrated that idiosyncratic drug-induced agranulocytosis is a relative rare events; that antibiotics, antithyroid, neuroleptic and anti-epileptic agents, and platelet aggregation inhibitors are the main incriminated drug classes; that agranulocytosis typically serious, with at least 50% exhibiting severe sepsis and a mortality rate <10%; and that modern management of such disorder may reduce the infection-related mortality. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

59. [Therapeutic aspects in the management of hairy cell leukemia]

Author

Maloisel F, Andrès E, Troussard X, Herbrecht R, and Dufour P

Subjects
Survival Rate, Leukemia, Hairy Cell, Antibiotics, Antineoplastic, Dose-Response Relationship, Drug, Humans, Interferons, Pentostatin
Abstract

CHRONIC B CELL PROLIFERATION: An estimated 80 to 120 new cases of hairy cell leukemia are diagnosed annually in France. Median survival is 5 years for untreated patients who develop a series of infectious complications. For many years, interferon alpha was the standard therapy but the therapeutic strategy has changed with the arrival of purine analogs, deoxycoformicine and 2-CdA.We searched Medline, Pascal, and Current Contents for literature on the treatment of hairy cell leukemia over the last 10 years and discuss here available data on response rate, mechanism of action and adverse effects of different therapeutic options. BY TREATMENT: Interferon generally induces partial response and most patients relapse after treatment withdrawal. The purine analogs, desoxycoformycine and 2-chlorodeoxyadenosine, are more active than interferon inducing response in approximately 90% of the cases, even after interferon failure, complete response is achieved in 50% to 70% of patients. Relapse rate at 5 years appears to be limited to 10% n 15%. Besides infections, the main adverse effect is the constant deep and persistent decline in CD4 counts but with no special risk of opportunistic infection. The increased rate of secondary cancers in long-term survivors and its possible relationship with treatments remains a controversial topic.

Published
1999

60. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Author

Feldman, E. J., Cortes, J., DeAngelo, D. J., Holyoake, T., Simonsson, Bengt, O'Brien, S. G., Reiffers, J., Turner, A. R., Roboz, G. J., Lipton, J. H., Maloisel, F., Colombat, P., Martinelli, G., Nielsen, J. L., Petersdorf, S., Guilhot, F., Barker, J., Kirschmeier, P., Frank, E., Statkevich, P., Zhu, Y., Loechner, S., List, A., Feldman, E. J., Cortes, J., DeAngelo, D. J., Holyoake, T., Simonsson, Bengt, O'Brien, S. G., Reiffers, J., Turner, A. R., Roboz, G. J., Lipton, J. H., Maloisel, F., Colombat, P., Martinelli, G., Nielsen, J. L., Petersdorf, S., Guilhot, F., Barker, J., Kirschmeier, P., Frank, E., Statkevich, P., Zhu, Y., Loechner, S., and List, A.

Abstract

Lonafarnib is an orally bio-available farnesyltransferase inhibitor that prevents farnesylation of specific target proteins including Ras. In a multicenter study, 67 patients with advanced myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) were treated with a continuous oral dose of 200-300 mg of lonafarnib and were evaluated for hematologic, pathologic and pharmacodynamic response. The median age of patients was 70 years (range 44-86). There were 32 patients with MDS (RAEB-20 and RAEB-t-12) and 35 with CMML. Overall 16 (24%) of the patients responded with two patients achieving a complete remission and one a partial response. Responses were seen in 6/32 and 10/35 patients with MDS and CMML, respectively. Of the 19 patients who were platelet transfusion-dependent prior to treatment, 5 (26%) became transfusion-free for a median duration of 185 days. A decrease in the farnesylation of the HDJ-2 protein measured in patient-derived cells was observed in the majority of patients during treatment with lonafarnib, but no clear correlation between changes in farnesylation and clinical effect could be made. Gastrointestinal toxicity was significant with 19% of patients discontinuing therapy due to diarrhea, nausea and/or anorexia. Lonafarnib has demonstrable activity in patients with advanced MDS and CMML.

Published
2008
Full Text
View/download PDF

62. [Pseudo-acute surgical abdomen and acute leukemia]

Author

Je, Kurtz, Maloisel F, Emmanuel Andres, Rohr S, and Oberling F

Subjects
Abdomen, Acute, Adult, Diagnosis, Differential, Male, Viscera, Leukemia, Leukemic Infiltration, Acute Disease, Humans, Female, Middle Aged, Tomography, X-Ray Computed, Aged
Abstract

The so-called pseudo-acute abdomen has been reported in acute leukemia, both at diagnosis or relapse. The clinical presentation may be misleading and life-threatening, due to the possible infiltration of any abdominal viscera. The authors present a series of eight patients and emphasize the management specificities of such patients and the possibility of long-term remissions, regardless of the severity of the initial presentation.

Published
1998

63. Stem cell factor in combination with figrastim following chemotherapy improves peripheral blood progenitor cell mobilisation

Author

Harousseau, J.l., Facon, T, Maloisel, F., Attal, M., Odriozola, J., Alegre, A., Schroyens, W., Hulin, C., Marin, P., Schots, Henri, Guilhot, F., Granena, A., De Waele, Marc, Hematology, and Immunology and Microbiology

Subjects
Stem cells
Abstract

Objective: To determine wh ether addition of Stem Cell Factor (SCF, 20 ugJ kg/day) to a mobllization regimen consistlng of cyclophosphamide (CY), 4 gJ m2 and filgrastim 5 Ilg/kg/day could increase the CD34+ cell yield ,n the first leukapheresis (LK). Design and Melhods: A total of 102 multiple myeloma (MM) patlents (pis) we re enrolled inlo th,s randomised. conlrolled study at 14 sites. Cytokines (SCF + filgraslim: n = 55; filgrastlm; n = 47) were admlnlstered once daily after CY until LK were completed. LK started when WBC reached 4 x 109/L, and continued unlil a target yield of 5;( 106 CD34+ cells/kg was achieved or 4 LK performed. CD34+ cell enumeration was performed at a central laboratory blinded to treatment group. Prophylaclic anlihislamrnes were glven to all pts recelvlng SCF. Results: A slgnlficantly higher CD34+ cell yield was obtalned in the first LK of pts treated wlth SCF + filgraslim compared to those trealed wlth fitgrastim alone (median CD34+ cells: 11.9 vs 4.3

Published
1998

70. Acute myeloid leukemia complicating sarcoidosis

Author

Maloisel, F and Oberling, F

Subjects
Lung Diseases, Male, Porphyrias, Letter, Sarcoidosis, Glomerulonephritis, Membranoproliferative, Aspergillosis, Humans, Middle Aged, Liver Diseases, Alcoholic, Skin Diseases, Leukemia, Myelomonocytic, Acute
Published
1992

71. Outcome of Acute Promyelocytic Leukemia (APL) with Very High WBC Counts Treated with ATRA and Chemotherapy (CT): The European Group Experience.

Author

Kelaidi, C., primary, Chevret, S., primary, de Botton, S., primary, Raffoux, E., primary, Guerci, A., primary, Thomas, X., primary, Gardin, C., primary, Pigneux, A., primary, Stoppa, A., primary, Lamy, T., primary, Rigal-Huguet, F., primary, Vekhoff, A., primary, Meyer-Monard, S., primary, Chelo, R., primary, Pabst, T., primary, Chevalier, P., primary, Maloisel, F., primary, Deconinck, E., primary, Ferrant, A., primary, Bron, D., primary, Fegueux, N., primary, de la Serna, J., primary, Martin, G., primary, Cahn, J., primary, Ifrah, N., primary, Cassinat, B., primary, Dombret, H., primary, Sanz, M.A., primary, Fenaux, Pierre, primary, and Ades, L., primary

Published
2007
Full Text
View/download PDF

73. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

Author

Nicolini, F. E., primary, Hayette, S., additional, Corm, S., additional, Bachy, E., additional, Bories, D., additional, Tulliez, M., additional, Guilhot, F., additional, Legros, L., additional, Maloisel, F., additional, Kiladjian, J.-J., additional, Mahon, F.-X., additional, Le, Q.-H., additional, Michallet, M., additional, Roche-Lestienne, C., additional, and Preudhomme, C., additional

Published
2007
Full Text
View/download PDF

75. Cunninghamella bertholletiae: an uncommon agent of opportunistic fungal infection. Case report and review

Author

Maloisel, F., Dufour, P., Waller, J., Raoul Herbrecht, Marcellin, L., Koenig, H., Liu, K. L., Weber, J. -C, Bergerat, J. -P, Oberling, F., univOAK, Archive ouverte, Progression tumorale et microenvironnement. Approches translationnelles et épidémiologie, Institut Régional du Cancer-Université de Strasbourg (UNISTRA)-CHU Strasbourg-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC), Laboratoire d'Histoire des Sciences et de Philosophie - Archives Henri Poincaré (LHSP), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne A, hôpitaux universitaires de Strasbourg, 1, place de l’Hôpital, 67091 Strasbourg cedex, France, and Université de Strasbourg (UNISTRA)-CHU Strasbourg-Les Hôpitaux Universitaires de Strasbourg (HUS)-Institut Régional du Cancer-Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC)

Subjects
Opportunistic infection, Zygomycosis, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, cunninghamella bertholettiae, Deferoxamine, Aplastic anemia, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Cunninghamella bertholletiae is a fungus of the Zygomycetes class, Mucorales order. Only very few cases of disseminated infection have been reported. We observed a new case in a 19 years old man with severe aplastic anemia, due to pulmonary primoinfection and hematologic dissemination. This aplastic anemia failed to respond first to an antithymocyte globulin and steroid treatment and then to cyclosporine A. Deferoxamine was infused weekly to prevent iron overload. During a second antithymocyte globulin and steroid treatment, the patient developed bilateral pneumonia. Culture of the broncho-alveolar washing fluid established the diagnosis by isolation of C. bertholletiae. Despite amphotericin B and 5-fluorocytosine intravenous therapy, the patient died of disseminated infection six days after diagnosis, which was confirmed by necropsy. Underlying conditions, diagnosis and treatment are discussed, together with a review of the literature.

Published
1991

76. Variant Philadelphia-Positive Chronic Myeloid Leukemia, der(9) Deletions and Response to Imatinib Mesylate: A Retrospective Multicentric Analysis from the French Fi-LMC Group.

Author

Corm, S., primary, Nicolini, Franck, additional, Richebourg, S., additional, Huguet, F., additional, Rea, D., additional, Tigaud, I., additional, Dastugue, N., additional, Raynaud, S., additional, Legros, L., additional, van den Akker, J., additional, Mahon, F.X., additional, Maloisel, F., additional, Roche-Lestienne, C., additional, Guerci, A., additional, Preudhomme, C., additional, and Eclache, V., additional

Published
2006
Full Text
View/download PDF

78. Design and first interim analysis of a randomized phase III trial comparing imatinib versus imatinib (IM) based combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase

Author

Maloisel, F., primary, Dubruille, V., additional, Varet, B., additional, Escoffre-Barbe, M., additional, Berthaud, P., additional, Meresse, V., additional, Mahon, F., additional, Preudhomme, C., additional, Guilhot, J., additional, and Guilhot, F., additional

Published
2006
Full Text
View/download PDF

79. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Author

de Botton, S, primary, Sanz, M A, additional, Chevret, S, additional, Dombret, H, additional, Martin, G, additional, Thomas, X, additional, Mediavilla, J D, additional, Recher, C, additional, Ades, L, additional, Quesnel, B, additional, Brault, P, additional, Fey, M, additional, Wandt, H, additional, Machover, D, additional, Guerci, A, additional, Maloisel, F, additional, Stoppa, A M, additional, Rayon, C, additional, Ribera, J M, additional, Chomienne, C, additional, Degos, L, additional, and Fenaux, P, additional

Published
2005
Full Text
View/download PDF

80. A Multicenter Prospective Randomized Study Testing Non-Inferiority of Thalidomide 100 mg/day as Compared with 400 mg/day in Patients with Refractory/Relapsed Multiple Myeloma: First Results of the Final Analysis of the IFM 01-02 Study.

Author

Yakoub-Agha, Ibrahim, primary, Hulin, C., primary, Doyen, C., primary, Benboubker, L., primary, Voillat, L., primary, Bouabdallah, K., primary, Guillerm, G., primary, Moreau, P., primary, Maloisel, F., primary, Stoppa, A.M., primary, Pegourie, B., primary, Rodon, P., primary, Dib, M., primary, Casassus, P., primary, Slama, B., primary, Voog, E., primary, Jardel, H., primary, Collet, P., primary, Wettervald, M., primary, Peny, A.M., primary, Mineur, P., primary, Duguet, C., primary, Zerbib, R., primary, Facon, T., primary, and Mary, J.Y., primary

Published
2005
Full Text
View/download PDF

81. Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).

Author

Ades, L., primary, Raffoux, E., additional, Chevret, S., additional, de Botton, S., additional, Guerci, A., additional, Pigneux, A., additional, Stoppa, A.M., additional, Lamy, T., additional, Rigal-Huguet, F., additional, Vekhoff, A., additional, Pabst, T., additional, Meyer-Monard, S., additional, Maloisel, F., additional, Deconinck, E., additional, Caillot, D., additional, Gratecos, N., additional, Sotto, J.J., additional, Ferrant, A., additional, Turlure, P., additional, Thomas, X., additional, Fegueux, N., additional, Brault, P., additional, Reman, O., additional, Chevallier, P., additional, Travade, P., additional, Leblond, V., additional, Leverger, G., additional, Stamatoullas, A., additional, Pautas, C., additional, Beve, B., additional, Chomienne, C., additional, Dombret, H., additional, Degos, L., additional, and Fenaux, P., additional

Published
2004
Full Text
View/download PDF

88. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

Author

Pujade Lauraine, E, Guastalla, J, Colombo, N, Devillier, P, François, E, Fumoleau, P, Monnier, A, Nooy, M, Mignot, L, Bugat, R, Marques, C, Mousseau, M, Netter, G, Maloisel, F, Larbaoui, S, Brandely, M, Guastalla, JP, Brandely, M., COLOMBO, NICOLETTA, Pujade Lauraine, E, Guastalla, J, Colombo, N, Devillier, P, François, E, Fumoleau, P, Monnier, A, Nooy, M, Mignot, L, Bugat, R, Marques, C, Mousseau, M, Netter, G, Maloisel, F, Larbaoui, S, Brandely, M, Guastalla, JP, Brandely, M., and COLOMBO, NICOLETTA

Abstract

The purpose of this study was to evaluate the efficacy and tolerance of recombinant human interferon gamma (rIFN-gamma) as second-line treatment in patients with persistent disease at second-look laparotomy.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results